Possible relationship between the use of próton pump inhibitors and neoplasms
DOI:
https://doi.org/10.33448/rsd-v10i15.23310Keywords:
Proton bomb inhibitors; Stomach; Histopathological changes.Abstract
Introduction: The prolonged use of proton pump inhibitors has become common and has been widely applied in the treatment of these various gastrointestinal diseases and studies have shown a possible relationship between the use of these drugs and histopathological changes in the gastric region. Objective: To understand the possible relationship between the use of proton pump inhibitors (PPIs) and gastric disorders. Methodology: For this, the descriptors in the Bireme, Pubmed, Scielo databases were applied, considering the studies of the last 16 years. Expected results: The studies are expected to answer our questions and serve as a basis for further studies to be carried out. Conclusion: About the possible relationship between the use of proton pump inhibitors and cancer, it is important to emphasize that, with continuous use and in long-term therapy, this class of drug triggered hypergastrinemia in a large majority of patients and a high incidence of ECL cell hyperplasia. Regarding its association with H. pylori, positive patients who had been treated with PPIs for a long period had an increased risk of body atrophy compared to patients who were negative for Hp. Finally, there was no evidence of the association of PPIs with the induction or elevation of those rich in cancer.
References
Bittencourt, P. F. S. et al. (2006). Úlcera péptica gastroduodenal e infecção pelo Helicobacter pylori na criança e adolescente. Jornal de Pediatria. 82(5), 325-34.
Chinzon, D. et al. (2006). Refluxo gastroesofágico diagnóstico e tratamento. Rev AMRIGS, 50(3), 251-63
Ddine, L. C., Ddine, C. C., Rodrigues, C. C. R., Kirsten, V. R., & Colpo, E. (2012). Fatores associados com a gastrite crônica em pacientes com presença ou ausência do Helicobacter pylori. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 25, 96-100.
de Carvalho, A. S. (2000). Úlcera péptica. J. pediatr. S127-S134.
De Lima, A. P. V., & Filho Neto, M. D. A. (2013). Efeitos em longo prazo de inibidores da bomba de prótons. BJSCR.
Forgacs, I., & Loganayagam, A. (2008). Overprescribing proton pump inhibitors. BMJ (Clinical research ed.), 336(7634), 2–3. https://doi.org/10.1136/bmj.39406.449456.BE
Henry, M. A. C. D. A. (2014). Diagnóstico e tratamento da doença do refluxo gastroesofágico. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 27, 210-215.
Hoefler, R., & Leite, B. F. (2009). Segurança do uso contínuo de inibidores da bomba de prótons. Farmacoterapêutica, 14(1-2), 1-3.
Huang, L., Qi, D. J., He, W., & Xu, A. M. (2017). Omeprazole promotes carcinogenesis of fore-stomach in mice with co-stimulation of nitrosamine. Oncotarget, 8(41), 70332.
Jianu, C. S., Fossmark, R., Viset, T., Qvigstad, G., Sørdal, O., Mårvik, R., & Waldum, H. L. (2012). Gastric carcinoids after long-term use of a proton pump inhibitor. Alimentary pharmacology & therapeutics, 36(7), 644–649. https://doi.org/10.1111/apt.12012
Joo, M. K., Park, J. J. & Chun, H.J. (2019). Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol ; 25(17): 2058-2070 [PMID: 31114133 DOI: 10.3748/wjg.v25.i17.2058].
Lee, J. K., Merchant, S. A., Schneider, J. L., Jensen, C. D., Fireman, B. H., Quesenberry, C. P., & Corley, D. A. (2020). Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. The American journal of gastroenterology, 115(5), 706–715. https://doi.org/10.14309/ajg.0000000000000591
Lundell, L., Havu, N., Miettinen, P., Myrvold, H E, Wallin, L., Julkunen, R., Levander, K., Hatlebakk, J G, Liedman, B., Lamm, M., Malm, A., Walan, A. e (2006), Alterações da arquitetura da mucosa gástrica durante a terapia de omeprazol a longo prazo: resultados de um ensaio clínico randomizado. Alimentary Pharmacology & Therapeutics, 23: 639-647. https://doi.org/10.1111/j.1365-2036.2006.02792.x
McCarthy, D. M. (2020). Uso de inibidores da bomba de prótons, hipergastrinemia e carcinoides gástricos - qual é a relação? Jornal internacional de ciências moleculares, 21 (2), 662.
Morschel, C. F., Mafra, D., & Eduardo, J. C. C. (2018). Inibidores da bomba de prótons e sua relação com a doença renal. Brazilian Journal of Nephrology, 40, 301-306.
Nasser, S. C., Slim, M., Nassif, J.G. & Nasser, S. M. (2015). Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol. 21(15): 4599-4606; 10.3748/wjg.v21.i15.4599.
Ramakrishnan, K., & Salinas, R. C. (2007). Peptic ulcer disease. American family physician, 76(7), 1005–1012.
Rang, H.P.et al. (2007). Farmacologia. (6a ed.), Elsevier, 829 p.
Rindi, G., Fiocca, R., Morocutti, A., Jacobs, A., Miller, N., & Thjodleifsson, B. (2005). Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. European journal of gastroenterology & hepatology, 17(5), 559-566.
Souza, I. K. F. D., Silva, A. L. D., Araújo, A. J. D., Santos, F. C. B., & Mendonça, B. P. C. K. (2013). Análise qualitativa das alterações anatomopatológicas na mucosa gástrica decorrentes da terapêutica prolongada com inibidores da bomba de prótons: estudos experimentais x estudos clínicos. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 26, 328-334.
Tan, M. C., & Graham, D. Y. (2018). Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ evidence-based medicine, 23(3), 111-112.
Teixeira, T. F., Souza, I. D., & Rocha, R. D. R. (2016). Helicobacter pylori: infecção, diagnóstico laboratorial e tratamento. Percurso Acadêmico, 6(12), 1-11.
Wang, J., Shan, F., Li, S., Li, Z., & Wu, Q. (2021). Effect of administration of a proton pump inhibitor for ulcerative differentiated early gastric cancer prior to endoscopic submucosal dissection. Digestive Endoscopy, 33(6), 939-947.
Wannmacher, L. (2004). Inibidores da bomba de prótons: indicações racionais. Uso Racion Medicam Temas Selecionados, 2, 1-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Alyne de Araújo Paiva; Daniel Barbosa Lima; David Danisio Silva de Freitas; Francisco de Nojosa Costa Neto; Francisco Hildebrando Moreira de Oliveira Filho; Lucas Benjamim Pereira Farias; Maria das Graças Resende da Silva Neta; Ariellen Martins Guerra; Guilherme Araújo da Silva; Antônio Victor de Oliveira Machado ; Célia Barros de Sousa Marques ; Raquel Araújo Nogueira ; Ana Clara Correia Gomes ; José Lopes Pereira Júnior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
